UK Bill To Speed Up Post-Brexit Access To Innovative Drugs
Industry Welcomes Move, But Says Detail Lacking
A new bill giving the UK regulator more powers after Brexit has been welcomed by the life sciences industry. However, observers have warned that it needs fleshing out with detail, and that the government would be wise to proceed carefully if it considers relaxing clinical trial regulations.
